New predictors for immunotherapy responses sharpen our view of the tumour microenvironment
- 1 January 2020
- journal article
- editorial
- Published by Springer Nature in Nature
- Vol. 577 (7791) , 474-476
Abstract
Three studies reveal that the presence in tumours of two key immune components — B cells and tertiary lymphoid structures — is associated with favourable outcomes when individuals undergo immunotherapy. B cells are associated with favourable responses to immunotherapy.Keywords
This publication has 15 references indexed in Scilit:
- Tertiary lymphoid structures improve immunotherapy and survival in melanomaNature, 2020
- B cells are associated with survival and immunotherapy response in sarcomaNature, 2020
- B cells and tertiary lymphoid structures promote immunotherapy responseNature, 2020
- Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigensClinical Immunology, 2018
- Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non–Small Cell Lung Cancer PatientsCancer Immunology Research, 2017
- Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapyNature, 2015
- Characterization of tumor-associated B-cell subsets in patients with colorectal cancerOncotarget, 2014
- Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 2014
- Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cellsAutoimmunity Reviews, 2012
- Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic CorrelatesJournal of Clinical Oncology, 2010